Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the ...
Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results